Quantcast

In vitro performance of trans-valve left ventricular assist device installed at aortic valve position.

Research paper by Eiji E Okamoto, Tetsuya T Yano, Yusuke Y Inoue, Yasuyuki Y Shiraishi, Tomoyuki T Yambe, Yoshinori Y Mitamura

Indexed on: 28 Mar '20Published on: 28 Mar '20Published in: Artificial Organs



Abstract

In this study, we developed a trans-valve left ventricular assist device(LVAD) that unites a rear-impeller axial flow blood pump(AFBP) and a polymer membrane valve placed at the aortic valve position. The diameter and length of the rear impeller AFBP was 12 mm and 63 mm respectively. The polymer membrane valve was similar to the jelly-fish valve consisting of a valve leaflet made of silicon rubber(thickness 0.5 mm), valve ring (diameter:25 mm) and valve spokes. The trans-valve LVAD was examined in a mock circulation. An implantable pulsatile flow (PF) VAD was connected to an atrial reservoir to simulate the left ventricle, and the Hall valve was worn in the inflow port, and the trans-valve LVAD was placed in the outflow port as an outflow valve. When the motor rotational speed to 26400 rpm, the mean aortic flow increases from 4.2 L/min to 5.3 L/min , mean aortic pressure increased from 83.4 mmHg to 100 mmHg, and mean motor current of the implantable PF VAD decreased from 1.18 A to 0.94 A (unloading effect on left ventricle -21%). The energy equivalent pressure (EEP) increased from 85.2 mmHg to 102 mmHg, and surplus hemodynamic energy (SHE) decreased by -15.4% from the baseline. In conclusion, the trans-valve LVAD has an advantage of preserving pulsatility without any complicated mechanism and is a novel and promising LV support device. This article is protected by copyright. All rights reserved.